Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline

Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Emergex Receives Patent Protection for First-in-Class Influenza A Vaccines with Potential to Provide Long-Term T Cell Immunity.

Emergex Announces R&D Collaboration with DEKA Research & Development Corp.

Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates

Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate

Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine

Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox

Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma

Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine

Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil

Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch

Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives

Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate

Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus